GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Eli Lilly and Co (NYSE:LLY) » Definitions » Earnings per Share (Diluted)

Eli Lilly and Co (Eli Lilly and Co) Earnings per Share (Diluted) : $5.69 (TTM As of Dec. 2023)


View and export this data going back to 1970. Start your Free Trial

What is Eli Lilly and Co Earnings per Share (Diluted)?

Eli Lilly and Co's Earnings per Share (Diluted) for the three months ended in Dec. 2023 was $2.31. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $5.69.

Eli Lilly and Co's EPS (Basic) for the three months ended in Dec. 2023 was $2.31. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was $5.70.

Eli Lilly and Co's EPS without NRI for the three months ended in Dec. 2023 was $2.49. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was $8.81.

During the past 12 months, Eli Lilly and Co's average EPS without NRIGrowth Rate was -25.50% per year. During the past 3 years, the average EPS without NRIGrowth Rate was 0.80% per year. During the past 5 years, the average EPS without NRI Growth Rate was 8.60% per year. During the past 10 years, the average EPS without NRI Growth Rate was 11.50% per year.

During the past 13 years, Eli Lilly and Co's highest 3-Year average EPS without NRI Growth Rate was 80.00% per year. The lowest was -27.40% per year. And the median was 12.00% per year.


Eli Lilly and Co Earnings per Share (Diluted) Historical Data

The historical data trend for Eli Lilly and Co's Earnings per Share (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eli Lilly and Co Earnings per Share (Diluted) Chart

Eli Lilly and Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Earnings per Share (Diluted)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.89 6.79 6.12 6.90 5.80

Eli Lilly and Co Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Earnings per Share (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.04 1.49 1.95 -0.06 2.31

Competitive Comparison of Eli Lilly and Co's Earnings per Share (Diluted)

For the Drug Manufacturers - General subindustry, Eli Lilly and Co's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Eli Lilly and Co's PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Eli Lilly and Co's PE Ratio distribution charts can be found below:

* The bar in red indicates where Eli Lilly and Co's PE Ratio falls into.



Eli Lilly and Co Earnings per Share (Diluted) Calculation

Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.

Eli Lilly and Co's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2023 is calculated as

Diluted Earnings Per Share (A: Dec. 2023 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(5240.4-0)/903.284
=5.80

Eli Lilly and Co's Earnings Per Share (Diluted) for the quarter that ended in Dec. 2023 is calculated as

Diluted Earnings Per Share (Q: Dec. 2023 )=(Net Income - Preferred Dividends / Shares Outstanding (Diluted Average)
=(2189.7-0)/903.836
=2.42

Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $5.69

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.


Eli Lilly and Co  (NYSE:LLY) Earnings per Share (Diluted) Explanation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Eli Lilly and Co Earnings per Share (Diluted) Related Terms

Thank you for viewing the detailed overview of Eli Lilly and Co's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Eli Lilly and Co (Eli Lilly and Co) Business Description

Address
Lilly Corporate Center, Indianapolis, IN, USA, 46285
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.
Executives
Lilly Endowment Inc 10 percent owner 2801 NORTH MERIDIAN ST, INDIANAPOLIS IN 46208
Donald A Zakrowski officer: Chief Accounting Officer LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Alonzo Weems officer: SVP, ERM & CECO LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Patrik Jonsson officer: SVP and Pres., Lilly Bio-Meds LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Anne E. White officer: SVP & Pres-Lilly Oncology LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Eric Dozier officer: EVP, HR & Diversity LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Jackson P Tai director
Mary Lynne Hedley director C/O TESARO, INC., 1000 WINTER ST., STE 3300, WALTHAM MA 02451
Marschall S Runge director LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Naarden Jacob Van officer: SVP, CEO LoxoONC, Pres LlyONC C/O ELI LILLY & CO, LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Diogo Rau officer: SVP & CIDO LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Edgardo Hernandez officer: SVP & Pres., Mfg. Operations LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Kimberly H Johnson director C/O FANNIE MAE, 1100 15TH STREET, NW, WASHINGTON DC 20005
Anat Ashkenazi officer: SVP & CFO LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Gabrielle Sulzberger director 450 LEXINGTON AVENUE, FLOOR 13, NEW YORK NY 10017

Eli Lilly and Co (Eli Lilly and Co) Headlines

From GuruFocus

Eli Lilly and Co Guidance Call 2023 Transcript

By GuruFocus Research 01-23-2024

Eli Lilly and Co at Citi BioPharma Conference Transcript

By GuruFocus Research 01-23-2024

Q2 2023 Eli Lilly and Co Earnings Call Transcript

By GuruFocus Research 01-23-2024

Q3 2023 Eli Lilly and Co Earnings Call Transcript

By GuruFocus Research 01-23-2024